Gracell Biotechnologies Inc.
DelistedCIK 1826492fmd_09M38WK0DD9364P8YJVAAPH7Y8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2023, 8 periods
Latest annual · FY2022
Millions- Operating income
- (625)
- Net income
- (608)
- Free cash flow
- (531)
Gracell Biotechnologies Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -CN¥624.7 million | -CN¥463.6 million | 20-F 2023-04-25 · proof | |
| Net income | -CN¥607.5 million | -CN¥451.8 million | 20-F 2023-04-25 · proof | |
| Cash from operating activities | -CN¥482.6 million | -CN¥304.6 million | 20-F 2023-04-25 · proof | |
| Free cash flow | -CN¥531 million | -CN¥361.3 million | 20-F 2023-04-25 · proof | |
| Total assets | CN¥1.7 billion | CN¥2.1 billion | -19.6% | 20-F 2023-04-25 · proof |
| Total liabilities | CN¥280.5 million | CN¥232.8 million | +20.5% | 20-F 2023-04-25 · proof |
| Cash and cash equivalents | CN¥1.5 billion | CN¥1.8 billion | -20.5% | 20-F 2023-04-25 · proof |
| Total debt | CN¥158.9 million | CN¥122.8 million | +29.4% | 20-F 2023-04-25 · proof |
- What was Gracell Biotechnologies Inc.'s operating income in fiscal 2022?
- Gracell Biotechnologies Inc. reported operating income of -CN¥624.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -CN¥463.6 million the year before. Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What was Gracell Biotechnologies Inc.'s net income in fiscal 2022?
- Gracell Biotechnologies Inc. reported net income of -CN¥607.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -CN¥451.8 million the year before. Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What was Gracell Biotechnologies Inc.'s cash from operating activities in fiscal 2022?
- Gracell Biotechnologies Inc. reported cash from operating activities of -CN¥482.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -CN¥304.6 million the year before. Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What was Gracell Biotechnologies Inc.'s free cash flow in fiscal 2022?
- Gracell Biotechnologies Inc. reported free cash flow of -CN¥531 million for fiscal 2022 (the year ended Dec 31, 2022), against -CN¥361.3 million the year before. Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What are Gracell Biotechnologies Inc.'s total assets?
- As of Dec 31, 2022, Gracell Biotechnologies Inc. reported total assets of CN¥1.7 billion, against CN¥2.1 billion a year earlier (-19.6%). Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What are Gracell Biotechnologies Inc.'s total liabilities?
- As of Dec 31, 2022, Gracell Biotechnologies Inc. reported total liabilities of CN¥280.5 million, against CN¥232.8 million a year earlier (+20.5%). Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What are Gracell Biotechnologies Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Gracell Biotechnologies Inc. reported cash and cash equivalents of CN¥1.5 billion, against CN¥1.8 billion a year earlier (-20.5%). Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
- What is Gracell Biotechnologies Inc.'s total debt?
- As of Dec 31, 2022, Gracell Biotechnologies Inc. reported total debt of CN¥158.9 million, against CN¥122.8 million a year earlier (+29.4%). Source: the 20-F filed with the SEC on Apr 25, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1826492&period_type=annual&limit=5"Information only, not investment advice.